Literature DB >> 16436636

Mutually exclusive promoter hypermethylation patterns of hMLH1 and O6-methylguanine DNA methyltransferase in colorectal cancer.

Edward J Fox1, Dermot T Leahy, Robert Geraghty, Hugh E Mulcahy, David Fennelly, John M Hyland, Diarmuid P O'Donoghue, Kieran Sheahan.   

Abstract

Hypermethylation of CpG islands in gene promoter regions is an important mechanism of gene inactivation in cancer. Many cellular pathways, including DNA repair, are inactivated by this type of epigenetic lesion, resulting in proposed mutator phenotypes. Promoter hypermethylation of hMLH1 has been implicated in a subset of colorectal cancers that show microsatellite instability (MSI). Transcriptional silencing of O6-methylguanine DNA methyltransferase (MGMT) has also been described in a variety of neoplasms and has been associated with a consequent mutational spectrum. We investigated the relationship between hMLH1 promoter hypermethylation and MGMT promoter hypermethylation in 110 colorectal cancers using methylation-specific polymerase chain reaction. Expression of hMLH1 and MGMT was assessed by immunohistochemistry. MSI testing was performed using the National Cancer Institute consensus panel of five microsatellite markers. Promoter hypermethylation of hMLH1 was detected in 12% of tumors. This was significantly associated with the MSI-high phenotype (P < 0.01) and loss of hMLH1 expression (P < 0.01). Methylation of the MGMT promoter was detected in 43% of tumors, which were mostly microsatellite stable or MSI-low (P = 0.041) and showed loss of MGMT expression (P < 0.01). We demonstrated an inverse relationship between hMLH1 promoter hypermethylation and MGMT promoter hypermethylation (P = 0.041), suggesting that a number of distinct hypermethylation-associated pathways may exist in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16436636      PMCID: PMC1867561          DOI: 10.2353/jmoldx.2006.050084

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  56 in total

1.  Methylation of O(6)-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma.

Authors:  T J Park; S U Han; Y K Cho; W K Paik; Y B Kim; I K Lim
Journal:  Cancer       Date:  2001-12-01       Impact factor: 6.860

2.  O(6)-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer.

Authors:  P Wolf; Y C Hu; K Doffek; D Sidransky; S A Ahrendt
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

3.  Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis.

Authors:  M Esteller; R A Risques; M Toyota; G Capella; V Moreno; M A Peinado; S B Baylin; J G Herman
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

4.  Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent.

Authors:  K Ochs; B Kaina
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

5.  Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability.

Authors:  V L Whitehall; M D Walsh; J Young; B A Leggett; J R Jass
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

6.  Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene.

Authors:  M Nakamura; T Watanabe; Y Yonekawa; P Kleihues; H Ohgaki
Journal:  Carcinogenesis       Date:  2001-10       Impact factor: 4.944

7.  Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability.

Authors:  R Gafà; I Maestri; M Matteuzzi; A Santini; S Ferretti; L Cavazzini; G Lanza
Journal:  Cancer       Date:  2000-11-15       Impact factor: 6.860

8.  Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant.

Authors:  Maran J W Berends; Ying Wu; Rolf H Sijmons; Rob G J Mensink; Tineke van der Sluis; Jannet M Hordijk-Hos; Elisabeth G E de Vries; Harry Hollema; Arend Karrenbeld; Charles H C M Buys; Ate G J van der Zee; Robert M W Hofstra; Jan H Kleibeuker
Journal:  Am J Hum Genet       Date:  2002-01       Impact factor: 11.025

9.  On the quantitative relationship between O6-methylguanine residues in genomic DNA and production of sister-chromatid exchanges, mutations and lethal events in a Mer- human tumor cell line.

Authors:  A Rasouli-Nia; R Mirzayans; M C Paterson; R S Day
Journal:  Mutat Res       Date:  1994-03       Impact factor: 2.433

10.  Mutations of two PMS homologues in hereditary nonpolyposis colon cancer.

Authors:  N C Nicolaides; N Papadopoulos; B Liu; Y F Wei; K C Carter; S M Ruben; C A Rosen; W A Haseltine; R D Fleischmann; C M Fraser
Journal:  Nature       Date:  1994-09-01       Impact factor: 49.962

View more
  18 in total

Review 1.  Colorectal cancer: a model for epigenetic tumorigenesis.

Authors:  J J L Wong; N J Hawkins; R L Ward
Journal:  Gut       Date:  2006-07-13       Impact factor: 23.059

Review 2.  Molecular classification and correlates in colorectal cancer.

Authors:  Shuji Ogino; Ajay Goel
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

Review 3.  Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer.

Authors:  Diego M Marzese; Dave Sb Hoon
Journal:  Expert Rev Mol Diagn       Date:  2015-03-22       Impact factor: 5.225

4.  Low level of microsatellite instability correlates with short disease-free survival of gastric cancer patients undergoing neoadjuvant chemotherapy.

Authors:  Dan Jiang; Chang Shu; Weihan Zhang; Linyong Sun; Mengni Zhang; Yanjun He; Gemma Owen; Wanjun Jin; Du He; Xiangbing Deng; Xiaoyu Liu
Journal:  Virchows Arch       Date:  2020-06-25       Impact factor: 4.064

5.  Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer.

Authors:  Shuji Ogino; Takako Kawasaki; Gregory J Kirkner; Yuko Suemoto; Jeffrey A Meyerhardt; Charles S Fuchs
Journal:  Gut       Date:  2007-03-05       Impact factor: 23.059

6.  Promoter methylation status of MGMT, hMSH2, and hMLH1 and its relationship to corresponding protein expression and TP53 mutations in human esophageal squamous cell carcinoma.

Authors:  Yaoyao Su; Lihong Yin; Ran Liu; Jingyi Sheng; Miao Yang; Yi Wang; Enchun Pan; Wei Guo; Yuepu Pu; Juan Zhang; Geyu Liang
Journal:  Med Oncol       Date:  2013-12-24       Impact factor: 3.064

Review 7.  High throughput molecular diagnostics in bladder cancer - on the brink of clinical utility.

Authors:  Karsten Zieger
Journal:  Mol Oncol       Date:  2007-12-08       Impact factor: 6.603

Review 8.  In vivo biomarkers for targeting colorectal neoplasms.

Authors:  Pei-Lin Hsiung; Thomas Wang
Journal:  Cancer Biomark       Date:  2008       Impact factor: 4.388

9.  CpG methylation analysis--current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology.

Authors:  Antonia R Sepulveda; Dan Jones; Shuji Ogino; Wade Samowitz; Margaret L Gulley; Robin Edwards; Victor Levenson; Victoria M Pratt; Bin Yang; Khedoudja Nafa; Liying Yan; Patrick Vitazka
Journal:  J Mol Diagn       Date:  2009-06-18       Impact factor: 5.568

Review 10.  MLH1 promoter methylation frequency in colorectal cancer patients and related clinicopathological and molecular features.

Authors:  Xia Li; Xiaoping Yao; Yibaina Wang; Fulan Hu; Fan Wang; Liying Jiang; Yupeng Liu; Da Wang; Guizhi Sun; Yashuang Zhao
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.